Current view of the immunopathogenesis in inflammatory bowel disease and its implications for therapy.
Al though the aetiology of inflammatory bowel disease (IBD) remains unknown, the pathogenesis is gradually being unravelled, seeming to be the result of a combination of environmental, genetic, and immunological factors in which an uncontrolled immune response within the intestinal lumen leads to inflammation in genetically predisposed individuals. Multifactorial evidence suggests that a defect of innate immune response to microbial agents is involved in IBD. This editorial outlines the immunopathogenesis of IBD and their current and future therapy. We present IBD as a result of dysregulated mucosal response in the intestinal wall facilitated by defects in epithelial barrier function and the mucosal immune system with excessive production of cytokines growth factors, adhesion molecules, and reactive oxygen metabolites, resulting in tissue injury. Established and evolving therapies are discussed in the second part of this editorial and at the end of this section we review new therapies to modulate the immune system in patients with IBD.
Torres
M-I
MI
Rios
A
A
D000818:Animals; D017209:Apoptosis; D016207:Cytokines / Q000378:metabolism; D004032:Diet; D004043:Dietary Fiber / Q000378:metabolism; D005231:Fatty Acids, Unsaturated / Q000378:metabolism; D005419:Flavonoids / Q000378:metabolism; D006801:Humans; D007107:Immune System; D015212:Inflammatory Bowel Diseases / Q000453:epidemiology / Q000276:immunology* / Q000382:microbiology / Q000628:therapy*; D008957:Models, Genetic; D010972:Platelet Activating Factor / Q000378:metabolism; D019936:Probiotics / Q000378:metabolism; D017382:Reactive Oxygen Species
D016207:Cytokines; D004043:Dietary Fiber; D005231:Fatty Acids, Unsaturated; D005419:Flavonoids; D010972:Platelet Activating Factor; D017382:Reactive Oxygen Species